Introduction {#s01}
============

Cancerous tissues are typically stiffer than their normal counterparts because of increased deposition of collagen and other extracellular components. Extracellular density can also affect normal tissues. For example, mammographic density, defined by the ratio of stromal collagen to adipose tissue, may be a contributing risk factor for breast carcinoma ([@bib5]). ECM deposition and cross-linking is associated with matrix stiffness that in turn impacts cellular behavior by altering signaling pathways. Cells encountering stiff matrices respond by generating tension between the ECM and actin cytoskeleton; in contrast, cells in compliant tissue environments contract and remodel the ECM. Cells respond to perturbations in the extracellular mechanical microenvironment via integrins and other ECM receptors and funnel this information principally through cell matrix adhesions (CMAs). These large, dynamic assemblages of proteins function as "adhesomes," acting through interactions with the cytoskeleton to translate changes in ECM mechanics into cellular responses ([@bib37]; [@bib8]). Studies have documented how integrins and other collagen receptors mediate behavioral responses of cells to increased collagen deposition and matrix stiffness ([@bib47]; [@bib31]; [@bib49]), but much less is known about how other extracellular factors function in mechanotransduction.

SLITs are large, multidomain proteins that are part of the basement membrane, interacting with numerous ECM constituents, including heparin sulfate proteoglycans and collagen-XV/XVIII ([@bib3]). They signal through ROBO receptors, which belong to the immunoglobulin superfamily and contain no catalytic intracellular domains. Instead, ROBOs share several conserved regions that interact with adaptor proteins, such as Nck/Dock, and other signaling proteins, such as Rho GTPases ([@bib3]). These GTPases govern the contractile activity of cells in compliant environments and are also activated in response to extracellular stiffness. It is well established that Rho enhances contractility and builds cellular tension by regulating the actin cytoskeleton in response to ECM density and stiffness ([@bib47]; [@bib31]; [@bib33]). Recent evidence suggests that Rac may similarly function in enhancing intracellular tension by promoting the capture and assembly of MIIA minifilaments into maturing focal adhesions (FAs; [@bib30]). In addition, Rac activation can perpetuate a FAK--Cas--Rac feedback loop that generates and enhances intracellular tension ([@bib2]). These studies suggest a thus far underappreciated role for Rac in organizing the response of cells to external forces downstream of CMAs.

miRNAs exert profound effects on tissue morphology and function by controlling suites of genes during normal development and tumorigenesis. An example is *miR-203*, which has been shown to both suppress and enhance tumor progression through gene regulation ([@bib11]; [@bib4]). Many bona-fide *miR-203* targets have been identified, but none are located near the *miR-203* locus, suggesting that transcriptional regulation of *miR-203* is uncoupled from the protein coding genes it regulates ([@bib38]; [@bib41]). Currently, other than allelic deletion occurring in glioblastomas ([@bib12]), there is little information about regulatory mechanisms leading to the initial suppression of *miR-203* that occurs in different types of epithelial tumors. One possibility is that *miR-203* is regulated by global changes in tissue architecture arising during transformation. Indeed, ECM stiffness, which itself is regulated by tumor cells, has recently been shown to modulate miRNA expression, resulting in accelerated tumorigenesis ([@bib28]). Understudied, however, are the potential mechanisms used by cells to maintain tensional homeostasis and resist transformation in changing ECM environments. Here, we explore such a signaling circuit in which changes in ECM density and stiffness down-regulate *miR-203* expression, resulting in increased *Robo1* that serves a protective function by activating Rac and FAK to maintain cell shape and enhance CMAs.

Results {#s02}
=======

SLIT2/ROBO1 regulates actin organization in tissue and epithelial contraction in compliant matrices {#s03}
---------------------------------------------------------------------------------------------------

Breast cells sense physical changes in their microenvironment through CMAs and respond by modulating their cytoskeleton to mechanotransduce these extracellular alterations ([@bib13]; [@bib39]). One candidate pathway for regulating this behavior is the SLIT/ROBO family, originally identified through its role in axon guidance. During breast (mammary gland) development, ROBO1 expression is initially restricted to the outer myoepithelial layer of this bilayered tissue, but it is eventually expressed in the mature gland by a subset of inner luminal cells ([@bib42]; [@bib25]). In exploring ROBO1 function in the developing gland, we observed a marked morphologic change in *Robo1^−/−^* myoepithelial cells ([Fig. 1, A--C](#fig1){ref-type="fig"}). Cytokeratin-14 immunostaining of grazing tissue sections revealed that *Robo1^−/−^* myoepithelial cells are not as tightly packed as *Robo1^+/+^* cells. They also contain actin fibers that are significantly narrower than the broadly distributed actin fibers of *Robo1^+/+^* tissue. This suggested that loss of *Robo1* impacts the ability of these outer layer cells to organize their cytoskeleton.

![**SLIT2/ROBO1 regulates actin organization in the mammary gland and epithelial contraction of compliant matrices.** (A) Grazing sections of *Robo1^+/+^* and *Robo1^−/−^* murine mammary glands stained with Cytokeratin-14 (CK-14; red), phalloidin (green), and Hoechst (blue). Bars, 30 µm. (B and C) Quantification of fiber density (B) and fiber thickness (C) in grazing sections (*n* = 3 pairs of animals). (D) Cartoon depicting cell contraction in LD, 3D collagen gels. (E, H, J, and L) Representative micrographs of collagen gels containing (E) primary MECs, (H and J) NMuMG cells, and (L) MDA--MB-231 cells. Dashed outline represents measured area. (F, G, I, K, and M) Quantification of the percentage reduction in collagen gel area for gels embedded with *Robo1^+/+^* and *Robo1^−/−^* MECs (F and G), NMuMG cells treated with SLIT2 (I and K), and MDA--MB-231 cells infected with *Robo1* or scrambled (*SCR*) shRNA lentivirus (M) (*n* = 3 experiments). Asterisks denote significance by *t* test: \*, P \< 0.05; \*\*\*, P \< 0.001.](JCB_201507054_Fig1){#fig1}

To explore the behavior of *Robo1^+/+^* and *Robo1^−/−^* cells, we cultured primary mammary epithelial cells (MECs) in low-density (LD) gels. This generates a compliant 3D ECM that recapitulates the stiffness of normal mammary gland ([@bib31]) and is capable of being remodeled by resident MECs through cytoskeletal contraction of the collagen fibers ([Fig. 1 D](#fig1){ref-type="fig"}; [@bib15]). In this assay, cell contractility and tension are approximated by percentage reduction in gel size. We examined the effects of losing *Robo1* by culturing MECs, which express SLIT2 ([@bib42]) from mature virgin mice ([Fig. 1, E--G](#fig1){ref-type="fig"}). After 2 days in culture, gels containing *Robo1^+/+^* cells were 50% the area of gels containing *Robo1^−/−^* cells, which remained smaller over the 6-d time course, showing that *Robo1*^−/−^ MECs have a diminished capacity for contraction.

We also examined the effect of SLIT2/ROBO1 signaling on gel contraction using a nontransformed murine line (NMuMG) that is derived from normal glandular tissue and expresses ROBO1 similar to luminal cells harvested from a mature gland ([Fig. S1 A](http://www.jcb.org/cgi/content/full/jcb.201507054/DC1){#supp1}; [@bib42]). After 6 d in LD collagen, the gel size was reduced by ∼30% ([Fig. 1, H and I](#fig1){ref-type="fig"}). At this time, cultures were treated with SLIT2 (500 ng/ml), resulting in an additional twofold decrease in gel size. In contrast, NMuMG cells cultured in high-density (HD) collagen gels, which approximate the stiffness of the tumor microenvironment ([@bib31]), showed no reduction in gel size because the rigid ECM formed by high collagen concentration resists the cellular force exerted on it ([Fig. S2, A and B](http://www.jcb.org/cgi/content/full/jcb.201507054/DC1){#supp2}; [@bib47]; [@bib46]). Next, we titrated SLIT2 to a level that does not significantly inhibit cell proliferation ([Fig. S3, A and B](http://www.jcb.org/cgi/content/full/jcb.201507054/DC1){#supp3}) and performed the assay with this level of chronic SLIT2 (175 ng/ml; [Fig. 1, J and K](#fig1){ref-type="fig"}). Under this condition, gels contracted within 3 days, as opposed to 6 days for Mock treatment, and SLIT2-treated gels contracted significantly more each day. We also examined whether transformed cells display a similar behavior by knocking down *Robo1* in the basal-like cancer cell line, MDA--MB-231 that expresses *Robo1* despite being transformed, unlike other lines such as BT20 or SKBR3 (Fig. S3 C; [@bib25]; [@bib9]). Again, we observed a threefold decrease in gel contraction when *Robo1* expression is reduced ([Fig. 1, L and M](#fig1){ref-type="fig"}). Together, these experiments show that SLIT2/ROBO1 signaling enhances the ability of the cell's cytoskeleton to pull on collagen fibers, resulting in smaller gels in compliant environments.

SLIT/ROBO1 activates Rac signaling to modulate contractility {#s04}
------------------------------------------------------------

Cells use the Rho family of small GTPases to orchestrate the cytoskeletal changes that accompany ECM remodeling. Depending on cellular context, SLIT/ROBO signaling is capable of both suppressing and activating these small GTPases ([@bib3]). To assess the response of Rho and Rac to SLIT2 in mammary tissue and breast cells, we performed pull-down assays using GST fusion proteins that bind activated Rac/Cdc42 or Rho. We prepared lysates from cultured MECs, harvested from developing (5 wk) virgin glands and treated with Mock or SLIT2 (175 ng/ml). It was difficult to reproducibly detect activated Rho in MEC lysates ([Fig. S4 A](http://www.jcb.org/cgi/content/full/jcb.201507054/DC1){#supp4}). In contrast, we found an ∼2.5-fold increase in Rac activity upon SLIT2 treatment of wild-type MECs and a concordant ∼0.66-fold decrease in activated Rac in *Robo1^−/−^* MECs ([Fig. 2 A](#fig2){ref-type="fig"}). Because we observed a striking change in the morphology of the myoepithelial layer in *Robo1^−/−^* mammary gland tissue ([Fig. 1 A](#fig1){ref-type="fig"}), we further tested the specificity of Rac activation in isolated myoepithelial cells ([@bib24]). There was an approximately threefold increase in Rac activation in the *Robo1*-expressing myoepithelial fraction upon SLIT2 treatment ([Fig. 2 A](#fig2){ref-type="fig"}) and no change in the luminal fraction (Fig. S4 B). Because ROBO1 is expressed in basal cells during development and luminal cells in the mature gland, we also probed lysates generated from basal-like human breast epithelial cell line, HME50, and from the luminal NMuMG line, both of which express ROBO1 (Fig. S1 A). Again, there was a significant increase in Rac activity with SLIT2 treatment ([Fig. 2 A](#fig2){ref-type="fig"}).

![**SLIT2/ROBO1 signaling promotes Rac-mediated cell contraction of compliant matrices.** (A, top) Representative blots for GTP-Rac, total Rac, and GAPDH. (bottom) Quantification of Rac activation (*n* = 3 experiments). (B, D, and F) Images of 3D LD gels with embedded NMuMG cells subjected to indicated treatments: Mock, SLIT2, NSC23766 (NSC), *Sos1* or control siRNA, Y27632 (ROCK Inhibitor), or C3-Transferase (Rho inhibitor, C3-Trans). Dashed outline of gels represent measured areas. (C, E, and G) Quantification of the percentage reduction in collagen gel area for treated gels (*n* = 3 experiments). (H and J) Representative blots of pMRLC19, MRLC, and GAPDH from NMuMG cells treated with Mock or SLIT2 and indicated siRNA and inhibitors. (I and K) Quantification of pMRLC normalized to total MRLC and GAPDH (*n* = 3 experiments). Asterisks denote significance by *t* test: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; \*\*\*\*, P \< 0.0001. ns, not significant.](JCB_201507054_Fig2){#fig2}

Next, we investigated whether Rac activation is responsible for SLIT2/ROBO1-induced remodeling of collagen fibers and subsequent reduction in the size of compliant gels. We took advantage of a widely used Rac inhibitor (NSC23766) that targets two Rac-specific guanine nucleotide exchange factors (GEFs), TrioN and Tiam1. In contrast, a different GEF, Son of Sevenless 1 (Sos1), is responsible for activating Rac downstream of SLIT2/ROBO1 signaling ([@bib48]). We cultured NMuMG cells in LD collagen gels chronically treated with Mock, SLIT2 (175 ng/ml), and/or NSC2376 ([Fig. 2, B and C](#fig2){ref-type="fig"}). Similar to before ([Fig. 1, H and I](#fig1){ref-type="fig"}), we observed an ∼20% increase in gel contraction upon SLIT2 treatment. In contrast, treatment with NSC23766 dramatically inhibited contraction. Cotreatment of gels with NSC23766 + SLIT2, however, partially rescued the effect of the inhibitor, leading to an ∼20% increase in gel contraction, similar to the original increase observed with SLIT2. These data show that Rac plays an important role in cell-mediated collagen remodeling, which occurred under Mock but not inhibitor conditions and resulted in gel contraction. SLIT2 rescued the ability of cells to contract gels by activating Rac through a different GEF because this enhancement is observed in the presence of NSC23766 that inhibits TrioN and Tiam1, but not Sos1. We repeated the experiment in the presence of control (*Ctl*) or *Sos1* siRNA ([Fig. 2, D and E](#fig2){ref-type="fig"}). In the absence of NSC23766, we again observed significantly increased gel contraction with SLIT2 + *Ctl* siRNA treatment. This increase in contraction was significantly reduced by *Sos1* siRNA ([Fig. S5, F and G](http://www.jcb.org/cgi/content/full/jcb.201507054/DC1){#supp5}), to the level observed in Mock + *Sos1* siRNA ([Fig. 2, D and E](#fig2){ref-type="fig"}). In the presence of NSC23766, SLIT2, both alone and with *Ctl* siRNA, elicited gel contraction that was significantly greater than the contraction observed with SLIT2 + *Sos1* siRNA. Together, these data demonstrate that SLIT2/ROBO1 signaling activates Rac through Sos1, resulting in contraction of compliant collagen gels.

Although our data suggest that Rac is the major target of SLIT2 in MECs ([Fig. 2 A](#fig2){ref-type="fig"}), SLIT can also activate Rho (Fig. S4 A). To investigate whether Rho/ROCK is downstream of SLIT2/ROBO1 signaling in NMuMG cells in complaint environments, we performed contraction assays in the presence of either a Rho inhibitor, exoenzyme C3 Transferase, or ROCK inhibitor, Y27632 ([Fig. 2, F and G](#fig2){ref-type="fig"}). With Mock treatment there was very little contraction (\<3%). In contrast, SLIT2 treatment resulted in significantly increased contraction in the presence of the inhibitors. With ROCK inhibition, this increase was very small (\<5%), indicating that ROCK mediates contraction downstream of SLIT2/ROBO1/Rac signaling, consistent with its key role mediating contraction in compliant environments ([@bib47]). In contrast, with Rho inhibition, SLIT2 treatment resulted in a significantly greater degree of gel contraction (\>25%), consistent with cells activating Rac to mediate gel contraction under this condition. Because SLIT2 treatment alone resulted in more gel contraction than achieved with the SLIT2 + Rho inhibitor, the data do not rule out a role for Rho downstream of SLIT2/ROBO1 signaling. Although SLIT2 may activate both Rac and Rho to achieve maximal contraction, our data support a subsidiary role for Rho activation.

To remodel and reduce the size of the 3D collagen gels, cells apply tension to the collagen fibers. A major contributor to this dynamic cellular behavior is nonmuscle myosin II (NMII) that cross-links and contracts actin. NMII activity is enhanced by phosphorylation, especially on serine 19 of the myosin regulatory light chain (pMRLC19; [@bib1]). To evaluate if SLIT2/ROBO1 signaling increases pMRLC19 through Rac, NMuMG cells were treated with SLIT2 along with NSC23766, *Sos1*, and *Ctl* siRNA ([Fig. 2, H and I](#fig2){ref-type="fig"}). Compared with Mock, SLIT2 resulted in a trending but not significant increase in pMRLC19. Treating with NSC23766, however, significantly reduced pMRLC19 levels, which could then be significantly increased by SLIT2 treatment in a *Sos1*-dependent manner. Thus, SLIT2/ROBO1 signaling through Sos1 activated Rac and increased pMRLC19 when TrioN and Tiam1 were inhibited.

We also examined pMRLC19 levels in the presence of Rho (C3 Transferase) and ROCK (Y27632) inhibitors because ROCK directly phosphorylates MRLCS19 in response to Rho, while also indirectly increasing pMRLC19 by inhibiting myosin phosphatase ([@bib45]). We found that inhibiting either Rho or ROCK significantly diminished the level of pMRLC19, and this reduction was not mitigated by SLIT2 treatment ([Fig. 2, J and K](#fig2){ref-type="fig"}). Collectively, our studies suggest that although SLIT2/ROBO1 signaling may contribute to gel contraction by leading to MRLC activation, MRLC is not a primary target of SLIT2. Instead, additional targets downstream of ROBO1/Rac signaling are likely activated to achieve the enhanced gel contraction observed upon SLIT2 treatment.

SLIT2/ROBO1 activation of Rac increases FAK in CMAs {#s05}
---------------------------------------------------

Cells sense ECM changes through mechanosensitive receptors, assembling CMAs that conduct and translate these changes into cells ([@bib37]; [@bib8]). Our studies in compliant gels demonstrate that SLIT2/ROBO1 signaling enhances the ability of cells to pull on the ECM, possibility by increased signaling through CMAs. FAK is a major constituent of CMAs, functioning as a key mechanosensory protein. During CMA maturation, FAK activates by autophosphorylation on tyrosine 397 and subsequently phosphorylates and activates other proteins. We examined the phosphorylation status of FAK in NMuMG cells cultured in LD collagen with and without SLIT2 ([Fig. 3, A and B](#fig3){ref-type="fig"}). After 3 d, cells under Mock conditions were organized into nascent tubules with a diffuse low level of pFAK397 staining. In contrast, SLIT2 treatment resulted in irregularly shaped aggregates that contained a 20% increase in pFAK397 concentrated in large puncta. To confirm FAK activation by SLIT2, we treated NMuMG cells with SLIT2 (175 ng) and assayed pFAK397 by Western blot, observing a significant increase that was dependent on Sos1 ([Fig. 3, C and D](#fig3){ref-type="fig"}). In the presence of the Rac GEF inhibitor, NSC23766, there was a trending but not significant increase in pFAK397 upon SLIT2 treatment ([Fig. 3, E and F](#fig3){ref-type="fig"}). Knockdown of *Sos1* led to a significant decrease in baseline FAK397 phosphorylation in the absence or presence of NSC23766 ([Fig. 3, C--F](#fig3){ref-type="fig"}), suggesting that Rac activation through all three GEFs, but specifically Sos1 downstream of SLIT2/ROBO1 signaling, plays an important role in generating pFAK397.

![**SLIT2/ROBO1/Rac signaling increases pFAK397 in CMAs.** (A) Representative images of NMuMG cells in LD 3D collagen gels after Mock or SLIT2 treatment and stained for pFAK397 (red), phalloidin (green), and Hoechst (blue). White asterisks indicate nuclei. Arrowheads point to CMAs. (B) Mean percentage of the organoid (3+ nuclei) stained for pFAK397 (*n* = 12+ organoids). (C and E) Representative blots of pFAK397, total FAK, and GAPDH from NMuMG cells treated with Mock or SLIT2 and indicated siRNA and Rac Inhibitor, NSC. (D and F) Quantification of pFAK normalized to total FAK and GAPDH (*n* = 3 experiments). (G) NMuMG cells treated with Mock or SLIT2 and immunostained for pFAK397 (red), phalloidin (green), and Hoechst (blue). Arrows point to CMAs. (H) Quantification of pFAK397-labeled puncta (*n* = 3 experiments). (I, left) Representative images of NMuMG cells stained for pFAK397 (red), phalloidin (green), and Hoechst (blue); on right, FLAG (red). (inset left) Magnified images of boxed regions with arrowheads pointing to CMAs. (J) Quantification of pFAK397-labeled puncta (*n* = 3 experiments). (K) Representative images of 3D LD gels embedded with NMuMG cells transfected with control or *FAK* siRNA. (L and M) Quantification of K showing percentage reduction in collagen gel area (*n* = 3 experiments). Bars, 30 µm. Black asterisks denote significance by *t* test: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001; \*\*\*\*, P \< 0.0001.](JCB_201507054_Fig3){#fig3}

To better resolve whether these puncta represent FAs, we turned to single-cell immunocytochemical analysis using NMuMG cells because CMAs are difficult to detect in spindle-shaped HME50 cells. We plated NMuMG cells for 12 h, immunostained with pFAK397 and phalloidin, and then measured the size of peripheral pFAK397-positive puncta, located at the tips of labeled actin fibers. We found a threefold increase in the size of pFAK397-labeled puncta in SLIT2 treated cells ([Fig. 3, G and H](#fig3){ref-type="fig"}). Next, we investigated the consequences of activating Rac by infecting NMuMG cells with a constitutively active form and staining for pFAK397, FLAG, and phalloidin after 24 h (Adeno--FLAG--Rac L61; [Fig. 3, I and J](#fig3){ref-type="fig"}). Analysis revealed that cells expressing activated Rac had significantly larger FAs, similar in size to those observed in SLIT2-treated cells. To test whether gel contraction requires FAK activation, we reduced the expression of FAK ∼75% using siRNA (Fig. S5, A and B) and observed a significant decrease in the ability of cells to remodel the ECM and reduce gel size ([Fig. 3, K--M](#fig3){ref-type="fig"}). Together, these data suggest that recruitment of activated FAK to FAs is enhanced by SLIT2/ROBO1-activating Rac through Sos1 and that together this facilitates the contractile behavior of cells in compliant ECM environments.

ROBO1 is present in CMAs and its loss disrupts these structures {#s06}
---------------------------------------------------------------

Our data suggest that SLIT2/ROBO1 is involved in CMA signaling. We next asked whether ROBO1 is detected in these structures by performing immunocytochemistry on *Robo1^+/+^* and *Robo1^−/−^* MECs plated on fibronectin, using an antibody directed against the ROBO1 cytoplasmic domain. We observed ROBO1 distributed throughout the cell in a punctate pattern and observed colabeling of ROBO1 with FAK (∼40%) in peripheral puncta ([Fig. 4 A](#fig4){ref-type="fig"}). In *Robo1*^−/−^ cells there was little or no ROBO1 staining, and FAK was much less visible, particularly at the edges of cells where quantification revealed reduced accumulation in peripheral puncta ([Fig. 4, A and B](#fig4){ref-type="fig"}).

![**ROBO1 colocalizes and complexes with CMA components.** (A) Representative images of MECs from wild-type (*+/+*) and *Robo1^−/−^* mice stained for FAK (red), ROBO1 (green), and Hoechst (blue). Magnified boxed are the regions of +/+ cells; arrowheads point to colocalization. Bars, 10 µm. (B) Quantification of FAK-labeled FAs in MECs (*n* = 10+ cells). (C) Representative images of NMuMG cells infected with *Robo1* or scrambled (*SCR*) shRNA lentivirus and stained for GFP (green), phalloidin (red), and Hoechst (blue), and in next panel, pFAK397 (white). Inset: Magnified versions of boxed regions with dashed lines encircling FAs. (D) Quantification of the size of pFAK397-labeled puncta (*n* = 3 experiments). (E and F) Representative blots from column coimmunoprecipitation on HME50 (E) and NMuMG (F) using anti-PXN bait. Samples of flowthrough (FT), first and second wash (W1/W2), and first and second elutions (E1/E2) were blotted for PXN, FAK, ROBO1, and GAPDH. (G) Representative images of +/+ MECs stained for PXN (green), ROBO1 (red), and Hoechst (blue). Magnified boxed; arrowheads point to colocalization. Bars, 30 µm, unless labeled otherwise. Asterisks denote significance by *t* test: \*, P \< 0.05; \*\*, P \< 0.01.](JCB_201507054_Fig4){#fig4}

To further explore ROBO1's functional role in CMAs, we infected NMuMG cells with bicistronic *Robo1* shRNA-GFP (*shRobo1*) or scramble shRNA-GFP (*SCR*; Fig. S5, C and D), treated with SLIT2 and stained for pFAK397 and phalloidin ([Fig. 4, C and D](#fig4){ref-type="fig"}). Analyzing CMAs in GFP-positive knockdown cells, we observed reduced accumulation of pFAK397 in puncta in cells expressing *Robo1* shRNA. To determine if ROBO1 complexes with CMA proteins, we performed column coimmunoprecipitation using a paxillin (PXN) antibody covalently linked to beads ([Fig. 4, E and F](#fig4){ref-type="fig"}). Extracts from HME50 and NMuMG cells were passed over the column, followed by extensive washing, and finally elution of bound proteins. As expected, PXN was eluted after washing. In addition, we found FAK and ROBO1 in the eluted fractions, evidence that ROBO1 may be one of a large number of proteins that can be found associated with CMAs ([@bib16]). We also examined PXN and ROBO1 by immunocytochemistry on wild-type cells and observed their colocalization in puncta at the cell periphery ([Fig. 4 G](#fig4){ref-type="fig"}). Together, our data suggest that ROBO1 is both present in CMAs and plays a role in their maturation.

ECM stiffness up-regulates ROBO1 {#s07}
--------------------------------

To investigate how SLIT2/ROBO1 signaling responds to extracellular stiffness in a 3D environment, we cultured NMuMG cells in gels tuned to a defined stiffness (∼2,000 Pa) by controlling collagen concentration ([@bib31]). To examine CMAs, we subjected aggregated NMuMG cells to Mock or SLIT2 and stained with pFAK397 and phalloidin ([Fig. 5, A and B](#fig5){ref-type="fig"}). As previously observed ([Fig. 3, F and G](#fig3){ref-type="fig"}), SLIT2 resulted in robust recruitment of pFAK397 to CMAs detected as puncta at the end of labeled actin fibers. Next, we allowed cells to mature for 7 d in HD 3D culture before staining for ROBO1. In contrast with LD conditions where cells generate structures resembling a mammary tubule ([Fig. 5 C](#fig5){ref-type="fig"}), cells in HD gels appeared as clusters with dramatically up-regulated ROBO1 ([Fig. 5 C](#fig5){ref-type="fig"}), an eightfold increase revealed by Western blot ([Fig. 5 D](#fig5){ref-type="fig"}). To determine whether *Robo2* also exhibited such a dramatic response to extracellular collagen density, we extracted RNA from LD and HD gels and performed quantitative RT-PCR. There was no change in *Robo2* expression, but *Robo1* was significantly increased ([Fig. 5 E](#fig5){ref-type="fig"}), consistent with its up-regulation in microarray studies that compared LD/HD conditions ([@bib35]). We also examined whether *Robo1* is up-regulated in transformed cells under HD conditions by examining MDA--MB-231 cells. Again, we observed a significant up-regulation of *Robo1* expression in HD ([Fig. 5 F](#fig5){ref-type="fig"}).

![**ROBO1 up-regulation and pFAK397 FA enrichment occurs in high-stiffness 3D collagen systems.** (A) Representative images of NMuMG aggregates in HD 3D collagen gels treated with Mock or SLIT2 and stained for pFAK397 (red), phalloidin (green), and Hoechst (blue). (B) Area of pFAK397 puncta located at the end of phalloidin-labeled fibers in acini (3+ nuclei; *n* = 15+ acini). (C) Representative images of NMuMG acini in LD and HD 3D culture and stained for ROBO1 (green) and Hoechst (blue). (D--F) Analysis of ROBO1 protein (D) and mRNA (E and F) of mammary cells cultured in LD and HD collagen matrices for 7 d. (D, top) Quantification of ROBO1 protein normalized to GAPDH from NMuMG cells (*n* = 3 experiments). (bottom) Representative blots for ROBO1 and loading control GAPDH. (E and F) Expression of *Robo* mRNA in NMuMG (E) or MDA--MB-231 (F) cells from 7 d, 3D cultures (*n* = 3 experiments). (G) MCF10A acini cultured in 3D SAP gels were analyzed for *Robo1* (*n* = 3 experiments). (H) *Robo1* expression in NMuMG cells cultured in either LD detached (Dtch), LD attached (Atch), or HD (*n* = 3 experiments). For mRNA analysis, expression was normalized to *Gapdh* of total mRNA. Bars, 30 µm. White asterisks denote individual nuclei. Black asterisks denote significance by *t* test: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. ns, not significant.](JCB_201507054_Fig5){#fig5}

In these experiments, collagen concentration was increased to boost gel rigidity. Collagen, however, is a ligand for integrin and may stimulate integrin signaling. Consequently, the observed increase in *Robo1* expression may be a response to enhanced collagen-integrin signaling rather than ECM stiffness. To investigate, we increased ECM stiffness using synthetic self-assembling peptides (SAPs) to construct 3D extracellular microenvironments with tunable mechanical properties. When exposed to physiologic salt solutions, SAPs form fibrils that generate gels of defined stiffness depending on peptide concentration ([@bib26]). We performed these assays using a human nonmalignant cell line, MCF10A, that undergoes multicellular epithelial morphogenesis in compliant ECM environments ([@bib29]). Cells were cultured in Matrigel to form acini, transferred into SAP gels calibrated to low (600 Pa) or high (2,000 Pa) stiffness, and then harvested for quantitative RT-PCR analysis. In cells cultured in rigid SAP gels, we observed a fourfold increase in *Robo1* ([Fig. 5 G](#fig5){ref-type="fig"}). We also performed assays on NMuMG cells using LD gels cultured under attached (higher-stiffness) or detached (after 12 h, lower-stiffness) conditions ([@bib46]; [Fig. 5 H](#fig5){ref-type="fig"}). In the high-stiffness condition, we observed an approximately twofold increase in *Robo1* expression that is similar to the increase observed in HD 3D collagen gels but only one-half that observed in SAP gels. Previous studies have shown that even short periods of gel attachment allow cells to generate isometric tension because the matrix is restrained ([@bib22]). Thus, the relative up-regulation of *Robo1* in the detached/attached experiment is likely greater than what the data show because the detached gels were attached for 12 h while polymerizing. Collectively, these two studies, in which ligand concentration was held constant even as gel rigidity was increased, demonstrate that *Robo1* is up-regulated by ECM stiffness.

*miR-203* regulates *Robo1* in an ECM stiffness-dependent manner {#s08}
----------------------------------------------------------------

miRNAs control gene expression, thereby regulating many cellular processes, including the interaction of cells with the ECM. ECM stiffness, in turn, regulates the expression of many miRNAs ([@bib28]), one of which is *miR-203* that regulates *Robo1* by targeting binding sites in its 3′ UTR ([Fig. 6 A](#fig6){ref-type="fig"}). To determine whether extracellular stiffness governs *miR-203* expression in our assays, we examined its expression in NMuMG cells cultured in HD and LD collagen, in detached and attached LD gels, and in SAP gels ([Fig. 6, B--D](#fig6){ref-type="fig"}). In all cases, *miR-203* was significantly down-regulated by high stiffness, correlating with *Robo1* up-regulation ([Fig. 5, C and D](#fig5){ref-type="fig"}).

![**ECM stiffness inhibits *miR-203* expression and elevates *Robo1* expression to regulate mammary cell contraction and organoid morphology and is associated with improved survival.** (A) Cartoon of four *miR-203* binding sites on *Robo1*'s 3′UTR. (B--D) *MiR-203* expression analyzed from NMuMG cells cultured in LD or HD (B), LD detached (Dtch) or attached (Atch; C), or 3D SAP gels (D; *n* = 3 experiments). (E) *Robo1* expression analyzed from NMuMG cells transfected with an empty vector (EV), a vector overexpressing pre*miR-203*, or a vector overexpressing *Robo1* without a 3′UTR then cultured in LD or HD gels for 3 d (*n* = 3 experiments). (F) Representative images of LD gels from E, with dashed line encircling the gel area. (G) Quantification of the percent reduction in the gel area (*n* = 3 experiments). (H) Representative z-stack projections of MECs cultured in LD and HD collagen gels and stained for E-cadherin (red), phalloidin (green), and Hoechst (blue). Circular dashed lines mark lumens (L), and base of protrusions are traced by dashed lines. (I--J) Quantification of number (I) and length of protrusions (J) per organoid (*n* = 3 experiments). (K) Invasion assay using MDA--MB-231 cells. Arrowheads point to clusters of migrated cells (L) Scatterplot expression analysis of basal subtype breast tumors with low *miR-203* + high *Robo1* expressing samples indicated as blue dots and all other samples indicated as red dots. Percentage represents the proportion of samples: (low *miR-203* + high *Robo1* expressing tumors)/(total basal tumor; 22.4%; *n* = 142). (M) Survival curve analysis of indicated populations from K (*n* = 142). (N) Survival curve analysis of bottom and top 25% *Robo1* expressing basal tumor samples with Low *miR-203* + High *Robo1* expression (*n* = 30). Bars: (H) 30 µm; (K) 100 µm. Asterisks denote significance using *t* test: \*, P \< 0.05; \*\*, P \< 0.01; \*\*\*, P \< 0.001. Survival curve p-values determined using Renyi analysis, with weighted values of P = 0 and q = 1 optimized for long-term survival. Stiff, stiffness.](JCB_201507054_Fig6){#fig6}

This reduction in *miR-203* expression is expected to relieve its repression of *Robo1* and may be responsible for the increased *Robo1* expression in high-stiffness conditions ([Fig. 5, C--H](#fig5){ref-type="fig"}). To investigate, we overexpressed *miR-203* in NMuMG cells, embedded the cells in LD and HD gels, harvested them after 3 d, and evaluated *Robo1* levels by quantitative RT-PCR ([Fig. 6 E](#fig6){ref-type="fig"}). Overexpression of *miR-203* resulted in a significant decrease in *Robo1* expression, regardless of collagen density. This decrease was not observed when *Robo1* expression was reestablished in both HD and LD conditions by cotransfecting *miR-203* with a *Robo1* plasmid containing no *miR-203* binding sites ([Fig. 6 E](#fig6){ref-type="fig"}). Because HD gels do not contract, we probed the function of manipulating *miR-203* expression by overexpressing it in NMuMG cells and culturing them in LD gels ([Fig. 6, F and G](#fig6){ref-type="fig"}). As previously observed ([Fig. 1, H--K](#fig1){ref-type="fig"}), NMuMG cells pulled on the ECM and reduced gel size, but this ability was significantly inhibited by *miR-203* overexpression. We also cotransfected *miR-203* with *Robo1* plasmid and observed successful rescue of the cells' ability to contract the gels ([Fig. 6, F and G](#fig6){ref-type="fig"}). These data are consistent with a model in which increasing extracellular stiffness inhibits *miR-203* expression, resulting in *Robo1* up-regulation and an increased ability of cells to remodel the ECM in compliant environments.

Next, we cultured *Robo1^+/+^* and *Robo1^−/−^* primary MECs in LD and HD gels. These cells aggregated and proliferated to form bilayered acini-containing lumens ([@bib24]). We found that in LD gels, both *Robo1^+/+^* and *Robo1*^−/−^ colonies had multicellular protrusions of similar length, but there were significantly more protrusions when acini were generated using *Robo1^−/−^* cells ([Fig. 6, H--J](#fig6){ref-type="fig"}). We also observed these cellular extensions in HD gels, but under this condition there was not an increase in the number of extensions emanating from the *Robo1^−/−^* acini. Instead, we observed a significant increase in the length of the *Robo1^−/−^* extensions. This is in contrast with *Robo1^+/+^* acini that have significantly shorter protrusions in the HD condition. To further investigate, we performed invasion assays on MDA--MB-231 cells and found that knockdown of *Robo1* results in a threefold increase in invasiveness, suggesting that ROBO1 is involved in restricting the behavior of cells by maintaining cell shape and positional contact with the ECM ([Fig. 6 K](#fig6){ref-type="fig"} and Fig. S5 E).

Breast tumors have the ability to remodel their ECM to create a stiffened tumor microenvironment, leading us to interrogate publicly available clinical datasets for tumors displaying down-regulated *miR-203* and corresponding up-regulated *Robo1* expression. We focused on basal tumors (*n* = 142) because SLIT/ROBO signaling is most frequently altered in this tumor subtype ([@bib7]). We found that the percentage of basal tumors with a low *miR-203*/high *Robo1* expression pattern is 22.4% ([Fig. 6 L](#fig6){ref-type="fig"}). To evaluate clinical significance, we analyzed whether this inverse expression pattern improved the long-term survival of patients compared with those who do not have this signature. We found a significant increase in long-term survival for patients with basal tumors characterized by low *miR-203*/high *Robo1* ([Fig. 6 M](#fig6){ref-type="fig"}). Next, we stratified these low *miR-203*/high *Robo1* expressing basal tumors into lower and upper quartiles of *Robo1* expression, and they were analyzed for survivability. Again, we saw a significant increase in long-term survival for patients with basal tumors expressing higher levels of *Robo1* compared with those expressing lower levels ([Fig. 6 N](#fig6){ref-type="fig"}). Although these data do not take into consideration tumor stiffness, combined, our findings suggest that increasing *Robo1* occurs when the ECM stiffness down-regulates *miR-203*. This may function as a protective, homeostatic mechanism that maintains cell morphology in response to protumorigenic events, thereby significantly increasing the long-term survival of patients.

Discussion {#s09}
==========

At each stage of tumor development---initiation, promotion, and progression---changes in the microenvironment, specifically the molecular and physical characteristics of the ECM, influence cell behavior. Although much research focuses on the deleterious consequences to cells of these ECM changes, there has been less attention paid to the self-protective measures cells take in response to these changes. Here, we present our studies identifying an miRNA-based response to increased extracellular density that generates an antimetastasis barrier by up-regulating the tumor suppressor, *Robo1*, which, in turn, enhances CMAs. Previous studies have shown that SLIT2/ROBO1 signaling stabilizes cell--cell contacts by recruiting β-catenin to the cell membrane ([@bib34]; [@bib44]; [@bib24]). Here, our studies show that SLIT2/ROBO1 signaling also functions to enhance interactions with the ECM by boosting the size of FAs through Rac and FAK signaling ([Fig. 7](#fig7){ref-type="fig"}).

![**Cartoon model of SLIT2/ROBO1 signaling circuit.** (1) Increased ECM stiffness down-regulates *miR-203* derepressing *Robo1*. (2) ROBO1 expression is increased. (3) SLIT2/ROBO1 signals through Sos1/Rac to activate FAK; Rac also contributes to NMII activation. (4) This results in FA maturation and (5) enhanced cell contractility.](JCB_201507054_Fig7){#fig7}

ROBO1 is a well-characterized axon and cell guidance receptor ([@bib3]). Studies performed primarily in *Drosophila melanogaster* and some tumor cell lines show that it remodels the cytoskeleton via the direct and indirect interaction of its cytoplasmic domain with GTPase-activating proteins and GEFs and the abelson tyrosine and p21-activated kinases (PAKs; [@bib3]). ROBO1, like ROBO2, contains four conserved intracellular domains (CC0--CC3), whereas ROBO3 contains three domains, and ROBO4, which is expressed primarily in the vasculature, contains only two (CCO and CC2). Studies on ROBO4 have identified a PXN interaction motif that is located between the CCO and CC2 domains and directly interacts with PXN to inhibit Rac ([@bib19]). This region, however, is only poorly conserved in ROBO1. Consequently, even though we found that ROBO1 coimmunoprecipitates with PXN from breast cell lysates, it may be that this interaction is indirect rather than direct, consistent with ROBO1 being identified in only one of three replicate runs in a recent proteomic analysis of isolated FAs ([@bib21]). Structure/function studies in *Drosophila* have shown that the CC3/CC4 domains bind to the adaptor protein Dock/Nck, which recruits both the Rac GEF, Sos, and PAK ([@bib14]; [@bib48]). This stimulates a series of events with Sos activating Rac, which in turn activates PAK. Currently, there is controversy concerning whether Rac promotes or inhibits cellular contractility via PAKs or other mechanisms. There is evidence that Rac activation of PAK results in the phosphorylation of the NMII light chain and enhanced contraction through the regulation of the actin cytoskeleton and FAs ([@bib20]; [@bib6]; [@bib43]). Rac has also been shown to promote the PKC-dependent phosphorylation and recruitment of the NMII heavy chain to FAs ([@bib30]). Altogether, these data are consistent with our observations that SLIT2/ROBO1 signaling results in increased Rac and FAK activation and larger FAs. A more detailed analysis of the events occurring subsequent to ROBO1 activation will be required to fully understand the precise sequence of events that enable ROBO1 to enhance contractility in compliant environments while increasing cellular stability in stiff ones.

The cells of tissues are constantly monitoring their environment and responding to maintain external appearances. The comparatively stable outward appearance of adult organisms belies the continuous internal work of cells required to maintain homeostasis. One such kind of homeostasis is tensional homeostasis, whereby cells maintain defined levels of tension in relation to their surroundings, despite the application of mechanical stresses. Integrins are well-known mechanoresponsive receptors that generate signals to the cytoskeleton, which in turn responds by creating reciprocal intracellular contractility. We conclude from our studies that ROBO1 is a mechanoresponsive receptor that similarly functions to coordinate a cell's response to extracellular stiffness by regulating the actin cytoskeleton. Dysregulation of tensional homeostasis occurs in many tumor microenvironments and certainly contributes to the progression of breast cancer by driving the disorganization of the tissue ([@bib32]). SLIT/ROBO signaling is altered in many types of cancers, including breast, in which 40.7% of basal, 12.3% of luminal A, and 26.3% of luminal B type tumors display aberrant expression (Cancer Genome Atlas, 2012). Although the expression of *Slits* is usually silenced in tumors, the *Robo1* expression is variable, with some tumors silencing the gene ([@bib10]; [@bib27]) and others up-regulating it ([@bib9]). This likely explains the variability of *Robo1*'s description in the literature as tumor suppressor in some circumstances and oncogene in others ([@bib17]). In the breast, we observed that *Robo1* is up-regulated in response to increased ECM stiffness, which is associated with tumor formation. Eventually, however, only 20% of tumors contain a low *miR-203*/high *Robo1* gene signature, leading us to speculate that ROBO1 mediates a bimodal response. It is initially up-regulated by cells to act as a homeostatic mechanism that maintains intracellular tension and tissue integrity in response to protumorigenic events; this up-regulation is associated with improved breast cancer prognosis ([Fig. 6](#fig6){ref-type="fig"}; [@bib9]). Eventually, however, *Robo1* expression is frequently silenced by the tumor, or its function coopted to promote promigratory behaviors that facilitate metastasis. Nevertheless, as a "first" responder to transforming signals, with low *miR-203*/high *Robo1* expression patterns signifying a better survival prognosis, the SLIT2/ROBO1 pathway represents a potential therapeutic target for early stage breast cancer treatment.

Materials and methods {#s10}
=====================

Mouse strains {#s11}
-------------

*Robo1* mice were generated by inserting the LacZ gene between exons 3 and 4 using standard recombination techniques and genotyped using a PCR screen with the following primers: 5′-TGGCACGAAGGTATATGTGC-3′ forward primer for both wild-type and mutant alleles, 5′-GAAGGACTGGTGGTTTTGAG-3′ reverse primer for wild-type alleles, and 5′-CCTCCGCAAACTCCTATTTC-3′ reverse primer for mutant alleles ([@bib23]; [@bib42]). This study conformed to guidelines set by the University of California, Santa Cruz Animal Care Committee.

2D cell culture {#s12}
---------------

MDA--MB-231 cells were obtained from American Type Culture Collection and cultured in growth medium (DMEM; Gibco) supplemented with 10% heat-inactivated FBS (Atlanta Biologicals) and 1× penicillin streptomycin (Gibco; [@bib25]). HME50 were cultured in DMEM F12 Nutrient Mixture (Gibco) supplemented with 1× mammary epithelial growth supplement (Gibco) and 1× antibiotic-antimycotic (Gibco). NMuMG epithelial cells were obtained from Clonetics and cultured in growth medium supplemented with 10 µg/ml bovine insulin (Sigma-Aldrich). Primary MECs were harvested from tissue using combined collagenase type III (Worthington) and dispase class II digestion for 12 h, collected by 40-µm sieve filtration, and cultured in standard tissue culture conditions ([@bib24]). For FA immunofluorescence studies, cover-slips were acid washed for 12 h, autoclaved, and coated with human fibronectin (0.5 µg/cm^2^) for 45 min at 37°C. The slips were thoroughly rinsed with Dulbecco's PBS (Gibco) and dried in a sterile environment for 1 h before seeding cells ([@bib40]). For experiments using pharmacologic inhibitors, all treatments were 3 h at the following concentrations: SLIT2 (500 ng/ml), NSC23766 (10 µM), C3-exoenzyme (1.0 µg/ml), and Y27632 (10 µM).

3D collagen culture {#s13}
-------------------

NMuMG, MDA--MB-231, and primary murine MECs were cultured in rat tail collagen type I (BD; Corning) gels with concentrations optimized for compliancy and stiffness for each cell type by titrating each lot of collagen according to the manufacturer's recommendations ([@bib36]). Compliant, LD conditions were determined by greater than 30% contraction of the gels; and stiff, HD conditions were determined with the lowest concentration of collagen required for \<5% contraction of the gel. One day after the gels were cast in tissue culture, attached gels were left attached to the dish and remained at the bottom of media-filled wells. The detached gels were detached from the sides and bottom of the wells and allowed to float to the top of media-filled wells. Gels were fed with fresh media changed every 2--3 d. Gels were cultured for 3--14 d. For contractility studies, gels were imaged every 24 h using Bio-Rad ChemiDoc MP Imager and recorded with ImageLab software (Bio-Rad). Area of the gels was measured and analyzed using ImageJ (National Institutes of Health) and GraphPad Prism (GraphPad Software).

RNA extraction and quantitative RT-PCR {#s14}
--------------------------------------

Total RNA was harvested from cells embedded in collagen gels using TRIzol reagent (Invitrogen) and phase separated according to the manufacturer's protocols with an additional overnight RNA precipitation step in ethanol ([@bib24]). The RNA was further purified with TURBO DNase (Ambion) treatment. Total RNA quality was analyzed by agarose gel electrophoresis and quantified with an ND-1000 spectrophotometer (NanoDrop). cDNA libraries were prepared from 1 µg of total RNA using an iScript cDNA synthesis kit (Bio-Rad). *miR-203* and *U6* syntheses were prepared from 10 ng of total RNA using Tetro Reverse transcription (Bioline) and Taqman MicroRNA Assays (Life Technologies). Quantitative RT-PCR was performed in triplicate using LightCycler 480 SYBR Green I Master (Roche) and quantified using Bio-Rad CFX Connect Real-Time System and CFX Manager software (Bio-Rad). Results were normalized to GAPDH or U6. Primers used for quantitative PCR were as follows: Robo1-F: 5′-TTATGGTGATGTGGACCTTAGTA-3′, Robo1-R: 5′-GGTTGTATGGGATGGTTGGAG-3′, GAPDH: 5′-F-CATGGCCTTCCGTGTTCCTA-3′, and GAPDH-R: 5′-CCTGCTTCACCACCTTCTTGAT-3′, as previously described ([@bib18]).

Western blotting {#s15}
----------------

Protein lysates from adherent cells were prepared by direct lysing into 1× sample buffer and analyzed by Western blot. Lysates from 3D gel systems were made with 12-h incubation of diced gels in 2× RIPA buffer supplemented with 2× protease and phosphatase inhibitor cocktail 2 and 3 (Sigma-Aldrich) at 4°C. Sample buffer (4×) was added to the lysates, and protein analysis was done by Western blot. For phosphor blots, cells were treated 3 h with SLIT2 and the different inhibitors followed by harvest. Phosphospecific primary antibodies pFAK397 (SCBT), ROBO1 (Abcam), and pMRLC19 (Cell Signaling) were prepared in 4% BSA. Antibodies targeting MRLC (SCBT) and FAK (SCBT) were prepared in 5% milk. All proteins were detecting using clarity ECL or FEMTO chemiluminescent substrate (Bio-Rad) on a Bio-Rad ChemiDoc MP Imager and quantified using ImageLab or ImageJ software.

Coimmunoprecipitation {#s16}
---------------------

PXN antibody (SCBT) was purified using an Antibody Clean-Up kit (Pierce) and covalently conjugated to agarose beads in the Co-Immunoprecipitation kit (Pierce). Coimmunoprecipitation studies were conducted according to manufacturer protocols. Lysates, flow through, washes, and elutions were run on SDS-PAGE gels and analyzed via Western blot.

Invasion assay {#s17}
--------------

MDA--MB-231 cells were plated for 24 h and transfected with *Ctl* or *Sos1* siRNA using RNAiMAX (Invitrogen) for 24 h. Then, the cells were serum starved for 12 h. Cells were detached using EDTA, and each well was seeded with 200,000 cells in DMEM into the upper well. FBS (10%) was used as the chemoattractant in the bottom of each well. Invasion was allowed to occur for 4 h, then the top part of the upper wells were cleaned with cotton swabs. To visualize invaded cells, they were fixed in methanol and stained with 0.1% crystal violet. A mean of 10 images were taken per well using a 10× objective and quantified using ImageJ.

Immunofluorescence antibodies and imaging {#s18}
-----------------------------------------

Antibodies and markers used were as follows: pFAK397 (Invitrogen), PXN (SCBT), PXN (Thermo Fisher Scientific), FAK (BD Biosciences), ROBO1 (Abcam), E-Cad (R&D Systems), Alexa Fluor--546 phalloidin (Thermo Fisher Scientific) for actin fibers (Invitrogen), and Hoechst for nuclei (Invitrogen). The cells (2D) or gels (3D) were fixed in 4% paraformaldehyde in PBS for 15 min, washed in PBS for 10 min, and washed in 0.15 M glycine in PBS for 10 min on a shaker. Then they were permeabilized in 0.02% Triton in PBS for 10 min with a subsequent wash in PBS for another 10 min. The sample was then blocked using 10% serum (to secondary host animal) in PBS and incubated with primary antibody diluted in 5% serum in a humidified chamber for 12 h at 4°C or 1 h at RT. After three washes in PBS (2D) or five washes in PBS (3D) for 15 min each, the samples were incubated with secondary antibody and a nuclear stain diluted in 5% serum for 45 min in a humidified chamber at RT. Control samples were also incubated with secondary (without primary) to ensure specificity of antibodies. Samples and controls were washed three times in PBS for 15 min each. Gels (3D) had an additional wash in water for 10 min, then all samples were mounted onto slides or cover-slipped with Fluoromount-G (SouthernBiotech). Fluorescence images of 3D collagen gels were captured using PerkinElmer Volocity Spinning Disk Confocal Microscope. FAs in 2D culture were imaged on a Digital Widefield Microscope (BZ-9000; Keyence Biorevo).

Image analysis {#s19}
--------------

Assessment of actin fiber thickness was calculated in ImageJ and determined per cell. Each cell of a grazing section was identified by a nuclei in the plane of the cross section, and a straight line was drawn through the cell and perpendicular to the actin fibers. Along this line the intensity of the phalloidin stain was measured and is represented by peaks, where the width of the peaks represent the width of the fibers. The distance between the base of the peaks represents the relative distance between each fiber. Each N represents two age-matched littermates and the averaged measurements of at least 25 cells per animal. Measurements of matrix adhesions were also determined using ImageJ. Before analysis, the scale of the images was set using the calibrate function. Then, the adhesions were identified by zooming into peripheral regions of cells where clear puncta were found at the tips of phalloidin-labeled fibers. The phalloidin channel was reduced to barely visible for the puncta to be prominently displayed. Then, using the freehand tool in ImageJ, we circled the puncta and measured the area.

Rho/Rac activity assays {#s20}
-----------------------

Primary MECs and fractionated myoepithelial cells or HME50 and NMuMG cells were cultured as described in the 2D cell culture section and treated with SLIT2 at 70% confluency for 30 min before lysate preparation. Pull-downs from primary MECs required 36 glands per pull-down and from myoepithelial cells 80 glands per pull-down. Lysates were assayed for active GTPase levels by using the RhoA/Rac/Cdc42 Activation Assay Combo kit (Cell Biolabs) according to the manufacturer's protocols.

Plasmids, transfections, and infections {#s21}
---------------------------------------

Expression of recombinant proteins was conducted with either Lipofectamine 2000 (Thermo Fisher Scientific), RNAi-max (Thermo Fisher Scientific), or Polyethylenimine, Linear (MW 25,000; Polyscience)-mediated transfection with 3:1 transfectant-DNA ratio. Plasmids used for *Robo1* expression were based on the pSecTagB backbone (p-*Robo1*). Plasmids used for pre*miR203* overexpression were based on the pTarget backbone (p-miR203, p-EV, pRobo1-si: gift from S. Lakka, University of Illinois, Chicago, IL). Production of lentiviral particles for scrambled and *Robo1* knockdown experiments involved combination transfection of psPAX2, pMD2.G, and pLVTHM-scrambled-GFP (*SCR*) or pLVTHM-*shRobo1-GFP* (*shRobo1*) into HEK293T cells. Filtered (0.45 µm) viral particles were then diluted in media to infect target mammary lines (MDA--MB-231 and NMuMG). Constitutively active Rac production in NMuMG cells was accomplished by infection with adenovirus encoding *Rac L61* mutant (Ad-*FLAG-Rac L61*; Cell Biolabs) according to the manufacturer's recommendations.

Bioinformatics and statistics {#s22}
-----------------------------

To assess expression from publicly available breast tumor data, a TCGA-BRCA (breast cancer) data matrix was uploaded into the UCSC Cancer Browser Xena analysis tool. Data for basal subtype tumors were identified according to their PAM50 signature and further segregated into low and high *mir-203/Robo1* populations based on expression level. Survival curve (Kaplan--Meier) plots were constructed using GraphPad Prism. The p-values for the curves were determined using the *survdiff* function with weighted values of P = 0 and q = 1 within R. All other statistical analyses (*t* test, two-way analysis of variance) were conducted on GraphPad Prism. The p-values of \<0.05 were considered significant. Graph columns represent the mean, and error bars represent the SEM.

Online supplemental material {#s23}
----------------------------

Fig. S1 shows mammary cells expressing ROBO1. Fig. S2 shows HD collagen gels resist contractile forces from NMuMG cells even in the presence of SLIT2. Fig. S3 shows SLIT2 inhibits mammary cell proliferation. Fig. S4 shows SLIT2/ROBO1 modestly, but irreproducibly, activates Rho in MECs and does not activate Rac in luminal MECs. Fig. S5 shows the knockdown of Robo1, FAK, or Sos1 via lentivirus or siRNA. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201507054/DC1>.
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